175 related articles for article (PubMed ID: 2181072)
41. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
Lafreniere R; Rosenberg SA
J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
[TBL] [Abstract][Full Text] [Related]
42. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells.
Tilden AB; Itoh K; Balch CM
J Immunol; 1987 Feb; 138(4):1068-73. PubMed ID: 3100627
[TBL] [Abstract][Full Text] [Related]
43. Enhanced cytolytic activity of tumor infiltrating lymphocytes (TILs) derived from an ICAM-1 transfected tumor in a murine model.
Lefor AT; Fabian DF
J Surg Res; 1998 Feb; 75(1):49-53. PubMed ID: 9614856
[TBL] [Abstract][Full Text] [Related]
44. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
Kalland T; Belfrage H; Bhiladvala P; Hedlund G
J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
[TBL] [Abstract][Full Text] [Related]
45. Adoptive immunotherapy in tumor-bearing mice with OK-432-induced killer cells.
Ujiie T
Jpn J Exp Med; 1988 Apr; 58(2):109-14. PubMed ID: 3261814
[TBL] [Abstract][Full Text] [Related]
46. Synergy between recombinant interleukin 2 (rIL 2) and IL 2-depleted lymphokine-containing supernatants in facilitating allogeneic human cytolytic T lymphocyte responses in vitro.
Gately MK; Wilson DE; Wong HL
J Immunol; 1986 Feb; 136(4):1274-82. PubMed ID: 2418110
[TBL] [Abstract][Full Text] [Related]
47. [Effect of combined immunotherapy using two different BRMs; OK-432 and IL-2-cultured lymphocytes].
Kan N; Hori T; Ohgaki K; Inamoto T; Kodama H; Tobe T
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1298-306. PubMed ID: 3488027
[TBL] [Abstract][Full Text] [Related]
48. Distinct antitumor mechanisms of recombinant interleukin-2 on recombinant interleukin-2-activated killer-sensitive and -resistant murine tumors.
Maekawa R; Kitagawa T; Koizumi K; Sato K; Homma M
J Biol Response Mod; 1989 Dec; 8(6):676-90. PubMed ID: 2600605
[TBL] [Abstract][Full Text] [Related]
49. Mechanism of tumoricidal activity of OK-432-specific L3T4+ Lyt2- T-cells.
Ozaki S; Suginoshita T; Watanabe T; Obayashi H
Cancer Res; 1990 Aug; 50(15):4630-4. PubMed ID: 2369739
[TBL] [Abstract][Full Text] [Related]
50. Immunotherapy of murine hepatic metastases with lymphokine-activated killer cells expanded in serum-free media and recombinant interleukin 2.
Lafreniere R; Borkenhagen K; Bryant LD; Huchcroft S
Cancer Res; 1989 May; 49(9):2409-14. PubMed ID: 2565160
[TBL] [Abstract][Full Text] [Related]
51. Expression of high-affinity IL-4 receptors on murine tumour infiltrating lymphocytes and their up-regulation by IL-2.
Puri RK; Finbloom DS; Leland P; Mostowski H; Siegel JP
Immunology; 1990 Aug; 70(4):492-7. PubMed ID: 2203676
[TBL] [Abstract][Full Text] [Related]
52. Long-term interleukin 2-dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes from human squamous cell carcinomas of the head and neck.
Heo DS; Whiteside TL; Johnson JT; Chen KN; Barnes EL; Herberman RB
Cancer Res; 1987 Dec; 47(23):6353-62. PubMed ID: 3315186
[TBL] [Abstract][Full Text] [Related]
53. Augmentation of cytotoxicity of lymphokine activated killer cells on ovarian tumor cells by various biological response modifiers.
Nio Y; Zighelboim J; Berek JS; Bonavida B
Anticancer Res; 1990; 10(2A):441-6. PubMed ID: 2346317
[TBL] [Abstract][Full Text] [Related]
54. Murine trophoblast can be killed by lymphokine-activated killer cells.
Drake BL; Head JR
J Immunol; 1989 Jul; 143(1):9-14. PubMed ID: 2499634
[TBL] [Abstract][Full Text] [Related]
55. [Successful adoptive immunotherapy with OK432-inducible activated natural killer cells on tumor-bearing mice].
Yamaue H; Tanimura H; Iwahashi M; Tani M; Tsunoda T; Tabuse K
Nihon Gan Chiryo Gakkai Shi; 1989 Dec; 24(11):2546-55. PubMed ID: 2614190
[TBL] [Abstract][Full Text] [Related]
56. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
[TBL] [Abstract][Full Text] [Related]
57. Changes in tumor-associated NK 1.1+ large granular lymphocyte precursors after cyclophosphamide injection: in vitro characterization and potential therapeutic application.
Krupke DM; Fuller J; Aslakson C; Evans R
Nat Immun; 1994; 13(5):246-57. PubMed ID: 7833624
[TBL] [Abstract][Full Text] [Related]
58. Augmentation by OK-432 of generation of culture-induced killer cells.
Ujiie T
Jpn J Exp Med; 1987 Jun; 57(3):153-61. PubMed ID: 3682231
[TBL] [Abstract][Full Text] [Related]
59. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.
Lafreniere R; Rosenberg SA
Cancer Res; 1985 Aug; 45(8):3735-41. PubMed ID: 3893689
[TBL] [Abstract][Full Text] [Related]
60. Tumor necrosis factor-alpha enhances cytolytic activity of human natural killer cells.
Ostensen ME; Thiele DL; Lipsky PE
J Immunol; 1987 Jun; 138(12):4185-91. PubMed ID: 3108384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
